Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria

DISCUSSION: Ethnoracially diverse participants continue to be underrepresented in AD clinical trials. Several recommendations are provided to broaden eligibility criteria.PMID:34590409 | DOI:10.1002/alz.12433

Source: The Journal of Alzheimers Association - September 30, 2021 Category: Psychiatry Authors: Sanne Franzen Jade Emily Smith Esther van den Berg Monica Rivera Mindt Rozemarijn L van Bruchem-Visser Erin L Abner Lon S Schneider Niels D Prins Ganesh M Babulal Janne M Papma Source Type: research